Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | MMP9 | P14780 | 1/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.60 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16783292 | 0.92 | USP2 (0.52) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL5900952 | 0.86 | USP2 (0.57) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL25374005 | 0.85 | USP2 (0.50) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL223147 | 0.83 | USP2 (0.70) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL17491112 | 0.82 | USP2 (0.39) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL31599480 | 0.81 | TSHR (0.75) | USP2TSHRKDM4EALDH1A1LMNA | |
| Ethane Dimethane Sulfonate SCHEMBL1336145 | 0.81 | USP2 (0.75) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL13481842 | 0.80 | TSHR (0.38) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL565251 | 0.80 | USP2 (0.57) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL21616872 | 0.79 | TSHR (0.71) | USP2TSHRKDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 189 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250337021-A1 | ELECTRODE FOR LITHIUM ION BATTERIES, AND LITHIUM ION BATTERY | SUMITOMO SEIKA CHEMICALS (JP) | 2025-10-30 | — | — | US | disclosed |
| US-20250323274-A1 | LITHIUM-ION BATTERY ELECTRODE AND LITHIUM-ION BATTERY | SUMITOMO SEIKA CHEMICALS (JP) | 2025-10-16 | — | — | US | disclosed |
| EP-4510241-A1 | LITHIUM-ION BATTERY ELECTRODE AND LITHIUM-ION BATTERY | Sumitomo Seika Chemicals Co., Ltd. (JP) | 2025-02-19 | — | — | EP | disclosed |
| EP-4507038-A1 | ELECTRODE FOR LITHIUM ION BATTERIES, AND LITHIUM ION BATTERY | Sumitomo Seika Chemicals Co., Ltd. (JP) | 2025-02-12 | — | — | EP | disclosed |
| US-20220033394-A1 | COMPOUNDS FOR THE TREATMENT OF PAIN | ALKERMES, INC. | 2022-02-03 | — | — | US | disclosed |
| US-11180455-B2 | Compounds for the treatment of pain | ALKERMES, INC. | 2021-11-23 | — | — | US | disclosed |
| EP-3749667-A1 | COMPOUNDS FOR THE TREATMENT OF PAIN | Alkermes, Inc. (US) | 2020-12-16 | — | — | EP | disclosed |
| CN-111989327-A | Compounds for the treatment of pain | 奥克梅斯公司 | 2020-11-24 | — | — | CN | disclosed |
| US-10844076-B2 | Derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5-amine | NEKTAR THERAPEUTICS (US) | 2020-11-24 | — | — | US | disclosed |
| EP-3357922-B1 | 2-((5-(1-(3-(METHYLSULFONYL)PROPYL)PIPERIDIN-4-YL)PYRIDIN-2-YL)AMINO)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE DERIVATIVES AND RELATED COMPOUNDS AS CDK4 INHIBITORS FOR TREATING TUMORS | GUANGZHOU BEBETTER MEDICINE TECH CO LTD (CN) | 2020-08-26 | — | — | EP | disclosed |
| US-5932571-A | Substituted N-methyl-N-(4-(4-(1H-benzimidazol-2-yl) {1,4}diazepan-1-yl)-2-(aryl) butyl) benzamides useful for the treatment of allergic diseases | HOECHST MARION ROUSSEL, INC. (US) | 1999-08-03 | — | — | US | disclosed |
| US-5922737-A | Substituted N-methyl-N-(4-(4-(1H-Benzimidazol-2-YL-amino) piperidin-1-YL)-2-(arlyl) butyl) benzamides useful for the treatment of allergic diseases | HOECHST MARION ROUSSEL, INC. (US) | 1999-07-13 | — | — | US | disclosed |
| EP-0920425-A1 | SUBSTITUTED 4-(1H-BENZIMIDAZOL-2-YL-AMINO)PIPERIDINES USEFUL FOR THE TREATMENT OF ALLERGIC DISEASES | HOECHST MARION ROUSSEL, INC. (US) | 1999-06-09 | — | — | EP | disclosed |
| EP-0888338-A1 | NOVEL SUBSTITUTED N-METHYL-N-(4-(4-(1H-BENZIMIDAZOL-2-YL) 1,4]DIAZEPAN-1-YL)-2-(ARYL)BUTYL)BENZAMIDES USEFUL FOR THE TREATMENT OF ALLERGIC DISEASES | HOECHST MARION ROUSSEL, INC. (US) | 1999-01-07 | — | — | EP | disclosed |
| EP-0888336-A1 | NOVEL SUBSTITUTED N-METHYL-N-(4-(4-(1H-BENZIMIDAZOL-2-YL-AMINO)P IPERIDIN-1-YL)-2-(ARYL)BUTYL)BENZAMIDES USEFUL FOR THE TREATMENT OF ALLERGIC DISEASES | HOECHST MARION ROUSSEL, INC. (US) | 1999-01-07 | — | — | EP | disclosed |
| EP-0874843-A1 | NOVEL SUBSTITUTED 4-(1H-BENZIMIDAZOL-2-YL) 1,4]DIAZEPANES USEFUL FOR THE TREATMENT OF ALLERGIC DISEASES | HOECHST MARION ROUSSEL, INC. (US) | 1998-11-04 | — | — | EP | disclosed |
| WO-1997030989-A1 | NOVEL SUBSTITUTED N-METHYL-N-(4-(4-(1H-BENZIMIDAZOL-2-YL-AMINO)PIPERIDIN-1-YL)-2-(ARYL)BUTYL)BENZAMIDES USEFUL FOR THE TREATMENT OF ALLERGIC DISEASES | HOECHST MARION ROUSSEL, INC. (US) | 1997-08-28 | — | — | WO | disclosed |
| WO-1997030991-A1 | NOVEL SUBSTITUTED N-METHYL-N-(4-(4-(1H-BENZIMIDAZOL-2-YL)[1,4]DIAZEPAN-1-YL)-2-(ARYL)BUTYL)BENZAMIDES USEFUL FOR THE TREATMENT OF ALLERGIC DISEASES | HOECHST MARION ROUSSEL, INC. (US) | 1997-08-28 | — | — | WO | disclosed |
| WO-1997022604-A1 | NOVEL SUBSTITUTED 4-(1H-BENZIMIDAZOL-2-YL)[1,4]DIAZEPANES USEFUL FOR THE TREATMENT OF ALLERGIC DISEASES | HOECHST MARION ROUSSEL, INC. (US) | 1997-06-26 | — | — | WO | disclosed |
| WO-1997019074-A1 | SUBSTITUTED 4-(1H-BENZIMIDAZOL-2-YL-AMINO)PIPERIDINES USEFUL FOR THE TREATMENT OF ALLERGIC DISEASES | HOECHST MARION ROUSSEL, INC. (US) | 1997-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10844076-B2 | Derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5-amine | KCNJ2, TRPC5, RYR2 | USP2 4243/4885TSHR 508/4885KDM4E 1078/4885 |
| US-11180455-B2 | Compounds for the treatment of pain | OPRK1, OPRL1, ACHE | USP2 2873/4885TSHR 3710/4885KDM4E 4440/4885 |
| US-20220033394-A1 | COMPOUNDS FOR THE TREATMENT OF PAIN | OPRK1, OPRL1, ACHE | USP2 2873/4885TSHR 3710/4885KDM4E 4440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.